|
1
|
Marech I, Vacca A, Ranieri G, Gnoni A and
Dammacco F: Novel strategies in the treatment of
castration-resistant prostate cancer (Review). Int J Oncol.
40:1313–1320. 2012.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Wang Q, Li W, Zhang Y, et al: Androgen
receptor regulates a distinct transcription program in
androgen-independent prostate cancer. Cell. 138:245–256. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Power CA, Pwint H, Chan J, et al: A novel
model of bone-metastatic prostate cancer in immunocompetent mice.
Prostate. 69:1613–1623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zuluaga MF, Gabriel D and Lange N:
Enhanced prostate cancer targeting by modified protease sensitive
photosensitizer prodrugs. Mol Pharm. 9:1570–1579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pienta KJ, Abate-Shen C, Agus DB, et al:
The current state of preclinical prostate cancer animal models.
Prostate. 68:629–639. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosol TJ, Tannehill-Gregg SH, LeRoy BE,
Mandl S and Contag CH: Animal models of bone metastasis. Cancer.
97:748–757. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blouin S, Basle MF and Chappard D: Rat
models of bone metastases. Clin Exp Metastasis. 22:605–614. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh AS, Macpherson GR, Price DK, Schimel
D and Figg WD: Evaluation of human fetal bone implants in SCID mice
as a model of prostate cancer bone metastasis. Oncol Rep.
15:519–524. 2006.PubMed/NCBI
|
|
10
|
Song H, Shahverdi K, Huso DL, et al: An
immunotolerant HER-2/neu transgenic mouse model of metastatic
breast cancer. Clin Cancer Res. 14:6116–6124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arguello F, Baggs RB and Frantz CN: A
murine model of experimental metastasis to bone and bone marrow.
Cancer Res. 48:6876–6881. 1988.PubMed/NCBI
|
|
12
|
Jenkins DE, Hornig YS, Oei Y, Dusich J and
Purchio T: Bioluminescent human breast cancer cell lines that
permit rapid and sensitive in vivo detection of mammary tumors and
multiple metastases in immune- deficient mice. Breast Cancer Res.
7:R444–R454. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fritz V, Louis-Plence P, Apparailly F, et
al: Micro-CT combined with bioluminescence imaging: a dynamic
approach to detect early tumor-bone interaction in a tumor
osteolysis murine model. Bone. 40:1032–1040. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wetterwald A, van der Pluijm G, Que I, et
al: Optical imaging of cancer metastasis to bone marrow: a mouse
model of minimal residual disease. Am J Pathol. 160:1143–1153.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xing N, Chen Y, Mitchell SH and Young CY:
Quercetin inhibits the expression and function of the androgen
receptor in LNCaP prostate cancer cells. Carcinogenesis.
22:409–414. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Emadi BM, Soheili ZS, Schmitz I, Sameie S
and Schulz WA: Snail regulates cell survival and inhibits cellular
senescence in human metastatic prostate cancer cell lines. Cell
Biol Toxicol. 26:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen JN, Jiang Y, Li HG, et al:
Epstein-Barr virus genome polymorphisms of Epstein-Barr
virus-associated gastric carcinoma in gastric remnant carcinoma in
Guangzhou, Southern China, an endemic area of nasopharyngeal
carcinoma. Virus Res. 160:191–199. 2011. View Article : Google Scholar
|
|
18
|
Yang M, Jiang P, Sun FX, et al: A
fluorescent orthotopic bone metastasis model of human prostate
cancer. Cancer Res. 59:781–786. 1999.PubMed/NCBI
|
|
19
|
Guo Z, Yang X, Sun F, et al: A novel
androgen receptor splice variant is up-regulated during prostate
cancer progression and promotes androgen depletion-resistant
growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu HC, Hsieh JT, Gleave ME, Brown NM,
Pathak S and Chung LW: Derivation of androgen-independent human
LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Int J Cancer. 57:406–412. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hobisch A, Culig Z, Radmayr C, Bartsch G,
Klocker H and Hittmair A: Distant metastases from prostatic
carcinoma express androgen receptor protein. Cancer Res.
55:3068–3072. 1995.PubMed/NCBI
|
|
22
|
Brown RS, Edwards J, Dogan A, et al:
Amplification of the androgen receptor gene in bone metastases from
hormone-refractory prostate cancer. J Pathol. 198:237–244. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ullen A, Farnebo M, Thyrell L, et al:
Sorafenib induces apoptosis and autophagy in prostate cancer cells
in vitro. Int J Oncol. 37:15–20. 2010. View Article : Google Scholar
|
|
24
|
Liu Y, Wu X, Dong Z and Lu S: The
molecular mechanism of Vav3 oncogene on upregulation of androgen
receptor activity in prostate cancer cells. Int J Oncol.
36:623–633. 2010.PubMed/NCBI
|
|
25
|
Martin TA and Jiang WG: Anti-cancer agents
in medicinal chemistry (Formerly current medicinal chemistry -
Anti-cancer agents). Anticancer Agents Med Chem.
10:12010.PubMed/NCBI
|
|
26
|
Sturge J, Caley MP and Waxman J: Bone
metastasis in prostate cancer: emerging therapeutic strategies. Nat
Rev Clin Oncol. 8:357–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu TT, Sikes RA, Cui Q, et al:
Establishing human prostate cancer cell xenografts in bone:
induction of osteoblastic reaction by prostate-specific
antigen-producing tumors in athymic and SCID/bg mice using LNCaP
and lineage-derived metastatic sublines. Int J Cancer. 77:887–894.
1998. View Article : Google Scholar
|
|
28
|
Kleinman HK and Martin GR: Matrigel:
basement membrane matrix with biological activity. Semin Cancer
Biol. 15:378–386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tilghman RW, Blais EM, Cowan CR, et al:
Matrix rigidity regulates cancer cell growth by modulating cellular
metabolism and protein synthesis. PLoS One. 7:e372312012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thalmann GN, Anezinis PE, Chang SM, et al:
Androgen-independent cancer progression and bone metastasis in the
LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581.
1994.PubMed/NCBI
|
|
31
|
Xu J, Wang R, Xie ZH, et al: Prostate
cancer metastasis: role of the host microenvironment in promoting
epithelial to mesenchymal transition and increased bone and adrenal
gland metastasis. Prostate. 66:1664–1673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: at the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kogan-Sakin I, Tabach Y, Buganim Y, et al:
Mutant p53(R175H) upregulates Twist1 expression and promotes
epithelial-mesenchymal transition in immortalized prostate cells.
Cell Death Differ. 18:271–281. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kong D, Banerjee S, Ahmad A, et al:
Epithelial to mesenchymal transition is mechanistically linked with
stem cell signatures in prostate cancer cells. PLoS One.
5:e124452010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Birchmeier C, Birchmeier W and
Brand-Saberi B: Epithelial-mesenchymal transitions in cancer
progression. Acta Anat. 156:217–226. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grille SJ, Bellacosa A, Upson J, et al:
The protein kinase Akt induces epithelial mesenchymal transition
and promotes enhanced motility and invasiveness of squamous cell
carcinoma lines. Cancer Res. 63:2172–2178. 2003.PubMed/NCBI
|
|
37
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005.
|
|
39
|
Wells A, Yates C and Shepard CR:
E-cadherin as an indicator of mesenchymal to epithelial reverting
transitions during the metastatic seeding of disseminated
carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
